You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TROP2

Showing 1 - 25 of 628
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)

Not yet recruiting
  • Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Breast Cancer Trial in Beijing (99mTc-MY6349 SPECT/CT scan)

Recruiting
  • Breast Cancer
  • 99mTc-MY6349 SPECT/CT scan
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 24, 2023

TNBC - Triple-Negative Breast Cancer Trial (A1:SG with SHR3680, A2:SG, B1:SG with SHR1210)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • A1:SG with SHR3680
  • +7 more
  • (no location specified)
Jun 23, 2023

Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma Trial in Houston (TROP2-CAR-NK, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Pancreatic Cancer
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 27, 2023

Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

Not yet recruiting
  • Triple-negative Breast Cancer
  • A1: SHR-A1811
  • +11 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 19, 2023

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Withdrawn
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Jan 24, 2023

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)

Not yet recruiting
  • Esophagogastric Adenocarcinoma
  • Sacituzumab govitecan
  • (no location specified)
Nov 9, 2023

Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)

Active, not recruiting
  • Breast Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 11, 2023

Cervical Cancer Trial (Sacituzumab Govitecan)

Not yet recruiting
  • Cervical Cancer
  • Sacituzumab Govitecan
  • (no location specified)
Apr 18, 2023

Breast Cancer Trial in Xiamen (ICG-SG incubation solution)

Recruiting
  • Breast Cancer
  • ICG-SG incubation solution
  • Xiamen, Fujian, China
    Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medi
Jan 23, 2023

Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

Not yet recruiting
  • Ovarian Carcinoma
  • Sacituzumab govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 31, 2023

Advanced Solid Tumors Trial (BAT8008 for Injection)

Not yet recruiting
  • Advanced Solid Tumors
  • BAT8008 for Injection
  • (no location specified)
Nov 9, 2022

Advanced Solid Tumors Trial in Beijing, Shanghai (JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection))

Recruiting
  • Advanced Solid Tumors
  • JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)
  • Beijing, Beijing, China
  • +2 more
Apr 1, 2022

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Endometrial Carcinoma Trial in New Haven (Sacituzumab Govitecan)

Recruiting
  • Endometrial Carcinoma
  • Sacituzumab Govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Apr 4, 2022

Metastatic Lung Cancer Trial in Villejuif (DS-1062a)

Recruiting
  • Metastatic Lung Cancer
  • Villejuif, France
    Gustave Roussy
Jun 17, 2021

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in

Recruiting
  • Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2023

Gastrointestinal Cancer Trial (Capecitabine, Sacituzumab govetican)

Not yet recruiting
  • Gastrointestinal Cancer
  • (no location specified)
Oct 2, 2023

Epithelial Tumors, Malignant Trial in Randwick (MT-302 (A))

Recruiting
  • Epithelial Tumors, Malignant
  • MT-302 (A)
  • Randwick, New South Wales, Australia
    Scientia Clinical Research Ltd
Aug 1, 2023

Malignant Solid Tumors Trial (T60c injection)

Not yet recruiting
  • Malignant Solid Tumors
  • T60c injection
  • (no location specified)
Oct 7, 2023

Advanced or Metastatic Solid Tumor, Liver Failure Trial in United States (Sacituzumab Govitecan-hziy)

Recruiting
  • Advanced or Metastatic Solid Tumor
  • Liver Failure
  • Sacituzumab Govitecan-hziy
  • Long Beach, California
  • +5 more
Jan 6, 2023

NSCLC Trial in Worldwide (Datopotamab deruxtecan, Durvalumab, Carboplatin)

Recruiting
  • NSCLC
  • Datopotamab deruxtecan
  • +6 more
  • Phoenix, Arizona
  • +227 more
Jan 17, 2023

Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in Japan, United States (Datopotamab

Recruiting
  • Hormone Receptor Positive Breast Cancer
  • +2 more
  • Datopotamab Deruxtecan (Dato-DXd)
  • Los Angeles, California
  • +13 more
Jun 21, 2022